AtriCure, Inc. (ATRC)

NASDAQ • Healthcare

$55.14

+$1.54 (+2.9%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$52.51

Day Range$52 - $55.25

Avg. Volume (3M)1.7M

Market Cap$2.8B

P/E Ratio262.6

52 Week Range

$25.36$61.7

Next EarningsIn 31 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$153.6M100%

Gross Profitminus cost of goods$118.6M77%

Operating Incomeminus R&D and overhead$9.6M6%

Net Incomeminus taxes and the rest$8.9M6%

In plain terms: out of every $100 in revenue, AtriCure, Inc. keeps $6 as net profit.

Fundamentals & Financials

Revenue (TTM)

$569.6M

Net Income (TTM)

$10.5M

EPS (TTM)

$0.21

ROA (TTM)

1.56%

Current Ratio

4.22

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+13.3%Q3 2025-$0.13

+90.9%Q4 2025-$0.01

+249.9%Q1 2026$0.06

+103.1%Q2 2026$0

+10878.4%Q3 2026$0.18

Nov 4

in 31 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +10878.4%

AtriCure topped revenue expectations in the second fiscal quarter of 2026, reported July 23, 2026, as revenue rose 12.8% to about $153.6 million versus about $151.8 million expected, a 1.2% beat, and up from about $136.1 million a year ago. Sales were concentrated in the United States, which brought in about $125.6 million and grew 13.6%, while Asia Pacific climbed 15.4% to about $8.6 million. Gross profit came in at about $118.6 million, with gross margin near 77%, leaving the quarter’s profitability profile largely steady on the top-line mix. Operating cash flow was about $22.2 million, and the company repurchased $314,000 of stock. For the next period, consensus calls for EPS of $-0.04 on revenue of $151.2 million.

View full earnings history

About AtriCure, Inc.

AtriCure, Inc. develops and sells medical devices used in cardiac surgery and electrophysiology, making it part of the healthcare equipment field and listed on NASDAQ as ATRC. Its portfolio centers on ablation, appendage management, and soft-tissue closure, and it generated $534.5 million of revenue in FY2025.

Name

AtriCure, Inc.

CEO

Michael H. Carrel

Website

www.atricure.com

Industry

Healthcare

Year Founded

2000

Employees

1,350

Today's Snapshot

AI-generated

The day ended with ATRC 2.9% higher at 55.14, while its sector was flat. Freedom Capital Markets, an investment firm, downgraded AtriCure to Hold and raised its price target to $57.

Trading Volume

Above 10d avg 1.3M

1.6M

vs S&P 500 Today

Outperforming Market

+2.11%

Updated: October 2, 2026 at 20:18 UTC

Technical Indicators

3 Buy3 Neutral2 Sell

ATRC’s overall buy stance is driven mainly by a strong underlying trend—ADX is notably high—and the stock remains above longer-term averages despite trading below its short-term moving averages, indicating a pullback within a broader uptrend. Momentum is negative and short-term oscillators are subdued, while MACD is flat and volume (OBV) is soft, implying the retracement lacks heavy accumulation. Volatility is moderate per the ATR and the price sits near the classic pivot. Technical takeaway: the setup reads as a pausing uptrend—buy on trend-confirming signs but watch short-term weakness.

All signals